Small Molecules

10 Jan 2021 Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
10 Jan 2021 Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients
10 Jan 2021 Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
10 Jan 2021 U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
07 Jan 2021 UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis
06 Jan 2021 Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
06 Jan 2021 C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
06 Jan 2021 Biomea Fusion Raises $56 Million to Bring First Irreversible Menin Inhibitor into the Clinic and Advance Two Additional Irreversible Preclinical Programs
06 Jan 2021 Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient
06 Jan 2021 Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer
06 Jan 2021 Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
06 Jan 2021 Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds
06 Jan 2021 Farxiga granted Priority Review in the US for the treatment of patients with chronic kidney disease
05 Jan 2021 Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis
05 Jan 2021 BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
05 Jan 2021 IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor
05 Jan 2021 Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
05 Jan 2021 Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
04 Jan 2021 Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
04 Jan 2021 Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis
02 Jan 2021 Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
02 Jan 2021 Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
31 Dec 2020 Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
29 Dec 2020 Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
29 Dec 2020 Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top